BIOATLA, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
BIOATLA, INC. (BCAB) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $3.79 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-03-31
- BIOATLA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $3.79M, a 38.94% decline from fiscal 2023.
- BIOATLA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $6.21M, a 68.07% increase from fiscal 2022.
- BIOATLA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2022 was $3.69M, a 19.44% increase from fiscal 2021.
- BIOATLA, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2021 was $3.09M, a 283.02% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2024-12-31 | $3.79M 10-K · filed 2026-03-31 |
| 2023-12-31 | $6.21M 10-K · filed 2025-03-28 |
| 2022-12-31 | $3.69M 10-K · filed 2024-03-26 |
| 2021-12-31 | $3.09M 10-K · filed 2023-03-23 |
| 2020-12-31 | $807.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |